Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial.
Saved in:
| Title: | Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial. |
|---|---|
| Authors: | Huang, Haichao1 (AUTHOR), Wang, Tao1 (AUTHOR), Li, Wei1 (AUTHOR), Wu, Zhun1 (AUTHOR), Wang, Xuegang1 (AUTHOR), Xing, Jinchun1 (AUTHOR), Chen, Bin1,2 (AUTHOR) chenbin5557@163.com, Zhang, Kaiyan1,2 (AUTHOR) Kaiyanzhang_xmu@163.com |
| Source: | BMC Cancer. 3/10/2025, Vol. 25 Issue 1, p1-6. 6p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 14712407 |
|---|---|
| DOI: | 10.1186/s12885-025-13826-5 |
